Centessa Pharmaceuticals PLC - ADR

0
STU:260 (UK)   ADR
€ 14.10 (+1.44%) Oct 24
At Loss
P/B:
5.96
Market Cap:
€ 1.81B ($ 1.96B)
Enterprise V:
€ 1.62B ($ 1.75B)
Volume:
-
Avg Vol (2M):
100.00
Trade In:

Business Description

Centessa Pharmaceuticals PLC

ISIN : US1523091007

Share Class Description:

STU:260: ADR
Description
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
Name Current Vs Industry Vs History
Cash-To-Debt 3.44
Equity-to-Asset 0.72
Debt-to-Equity 0.3
Debt-to-EBITDA -0.58
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 7.3
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -128.1
3-Year EPS without NRI Growth Rate -118.7
3-Year FCF Growth Rate -123.2
Name Current Vs Industry Vs History
5-Day RSI 43.13
9-Day RSI 47.57
14-Day RSI 51.48
6-1 Month Momentum % 65.48
12-1 Month Momentum % 127.87

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 13.29
Quick Ratio 13.29
Cash Ratio 11.02

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.8
Shareholder Yield % -6.48

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -2268.45
Net Margin % -2296.03
FCF Margin % -2157.5
ROE % -61.74
ROA % -42.35
ROIC % -232.43
3-Year ROIIC % -235.12
ROC (Joel Greenblatt) % -1141.39
ROCE % -43.56